Electra Therapeutics upsized its U.S. IPO to raise nearly $350M, pricing 23.3M shares at $15 each on Nasdaq under ticker ETRA. The biotech plans to use proceeds for its lead asset ipsoprubart and working capital. Jefferies, TD Cowen, Evercore ISI, and Cantor are joint book-running managers.
Antibody therapy developer Electra upsizes IPO seeking nearly $350M
Login to unlock291characters for free
Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.